122 related articles for article (PubMed ID: 18176993)
1. Polymorphisms in genes encoding tumor necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis.
Pinto JA; Rego I; Rodríguez-Gomez M; Cañete JD; Fernandez-López C; Freire M; Fernandez-Sueiro JL; Sanmarti R; Blanco FJ
J Rheumatol; 2008 Jan; 35(1):177-8. PubMed ID: 18176993
[No Abstract] [Full Text] [Related]
2. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.
Criswell LA; Lum RF; Turner KN; Woehl B; Zhu Y; Wang J; Tiwari HK; Edberg JC; Kimberly RP; Moreland LW; Seldin MF; Bridges SL
Arthritis Rheum; 2004 Sep; 50(9):2750-6. PubMed ID: 15457442
[TBL] [Abstract][Full Text] [Related]
3. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.
Cuchacovich M; Ferreira L; Aliste M; Soto L; Cuenca J; Cruzat A; Gatica H; Schiattino I; Pérez C; Aguirre A; Salazar-Onfray F; Aguillón JC
Scand J Rheumatol; 2004; 33(4):228-32. PubMed ID: 15370717
[TBL] [Abstract][Full Text] [Related]
4. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients.
Martinez A; Salido M; Bonilla G; Pascual-Salcedo D; Fernandez-Arquero M; de Miguel S; Balsa A; de la Concha EG; Fernandez-Gutierrez B
Arthritis Rheum; 2004 Apr; 50(4):1077-82. PubMed ID: 15077289
[TBL] [Abstract][Full Text] [Related]
5. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis.
Miceli-Richard C; Comets E; Verstuyft C; Tamouza R; Loiseau P; Ravaud P; Kupper H; Becquemont L; Charron D; Mariette X
Ann Rheum Dis; 2008 Apr; 67(4):478-84. PubMed ID: 17673491
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density in patients with rheumatoid arthritis treated with infliximab.
Vis M; Voskuyl AE; Wolbink GJ; Dijkmans BA; Lems WF;
Ann Rheum Dis; 2005 Feb; 64(2):336-7. PubMed ID: 15647447
[No Abstract] [Full Text] [Related]
7. Tumor necrosis factor alpha haplotypes versus tumor necrosis factor alpha -308 G/A polymorphism in the prediction of infliximab treatment efficacy in rheumatoid arthritis.
Mugnier B; Roudier J
Arthritis Rheum; 2004 Dec; 50(12):4075-6; author reply 4076-7. PubMed ID: 15593229
[No Abstract] [Full Text] [Related]
8. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
9. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P
Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
[TBL] [Abstract][Full Text] [Related]
10. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism.
Chatzikyriakidou A; Georgiou I; Voulgari PV; Venetsanopoulou AI; Drosos AA
Rheumatology (Oxford); 2007 Jun; 46(6):1034-5. PubMed ID: 17409133
[No Abstract] [Full Text] [Related]
11. Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis.
Rojas-Villarraga A; Diaz FJ; Calvo-Páramo E; Salazar JC; Iglesias-Gamarra A; Mantilla RD; Anaya JM
J Autoimmun; 2009 Feb; 32(1):64-9. PubMed ID: 19117726
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics.
Fonseca JE; Carvalho T; Cruz M; Nero P; Sobral M; Mourão AF; Cavaleiro J; Ligeiro D; Abreu I; Carmo-Fonseca M; Branco JC
Ann Rheum Dis; 2005 May; 64(5):793-4. PubMed ID: 15834068
[No Abstract] [Full Text] [Related]
13. Infliximab improves vascular stiffness in patients with rheumatoid arthritis.
Wong M; Oakley SP; Young L; Jiang BY; Wierzbicki A; Panayi G; Chowienczyk P; Kirkham B
Ann Rheum Dis; 2009 Aug; 68(8):1277-84. PubMed ID: 18930987
[TBL] [Abstract][Full Text] [Related]
14. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells.
Tanino M; Matoba R; Nakamura S; Kameda H; Amano K; Okayama T; Nagasawa H; Suzuki K; Matsubara K; Takeuchi T
Biochem Biophys Res Commun; 2009 Sep; 387(2):261-5. PubMed ID: 19577537
[TBL] [Abstract][Full Text] [Related]
15. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
Chan CY; Browning JC; Larsen F; Hsu S
Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
[TBL] [Abstract][Full Text] [Related]
16. Genetic association of the major histocompatibility complex with rheumatoid arthritis implicates two non-DRB1 loci.
Vignal C; Bansal AT; Balding DJ; Binks MH; Dickson MC; Montgomery DS; Wilson AG
Arthritis Rheum; 2009 Jan; 60(1):53-62. PubMed ID: 19116923
[TBL] [Abstract][Full Text] [Related]
17. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
[No Abstract] [Full Text] [Related]
18. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
[TBL] [Abstract][Full Text] [Related]
19. Genetic epidemiology of rheumatoid arthritis.
Oliver JE; Worthington J; Silman AJ
Curr Opin Rheumatol; 2006 Mar; 18(2):141-6. PubMed ID: 16462519
[TBL] [Abstract][Full Text] [Related]
20. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
